URAC vs ACHC Specialty Pharmacy Accreditation — Which Should You Choose?

Last updated: April 2026

URAC and ACHC are the two dominant specialty pharmacy accreditors. Both satisfy PBM network requirements. Both unlock limited distribution drug access. But they differ in payer preference, standards focus, cost structure, and strategic value depending on your pharmacy type. This guide gives you a direct side-by-side comparison so you can make the right decision — or understand why dual accreditation may be your best path.

Why This Comparison Matters

Accreditation is not a checkbox — it is a market access strategy. With $265 billion in US specialty pharmaceutical dispensing revenue in 2024 and 75% of drugs in the clinical pipeline classified as specialty medications, the accreditation you hold determines which PBM networks you can join, which manufacturers will grant you dispensing contracts, and whether your pharmacy survives the ongoing PBM vertical integration wave.

Choosing between URAC and ACHC — or deciding to pursue both — is a strategic decision that affects your revenue for the next 3 years. IHS is a specialized healthcare accreditation consulting firm with over 25 years of URAC and NCQA expertise, and we advise on both URAC and ACHC pathways. Here is how they compare.

URAC vs ACHC Specialty Pharmacy: Side-by-Side Comparison

Both accreditations serve the same fundamental purpose — validating that your specialty pharmacy meets national quality standards — but they approach it differently.

Where URAC Has the Advantage

URAC holds clear advantages in three areas: commercial payer preference, clinical depth, and institutional fit.

Commercial Payer Preference

Approximately 66% of commercial payers prefer URAC accreditation for specialty pharmacy network inclusion. If your primary revenue stream comes from commercial payer contracts, URAC is the accreditation that carries more weight in network inclusion decisions. This preference is documented across multiple industry sources and reflects URAC's longer track record in the specialty pharmacy space.

Clinical Patient Management Depth

URAC's Patient Management (PM) module requires clinical assessments at therapy initiation, individualized care plans tailored to each patient's comorbidities and medication regimen, psychosocial barrier evaluation, and documented therapeutic interventions. This clinical depth exceeds what ACHC requires and positions URAC-accredited pharmacies as clinically advanced in payer negotiations. It also means URAC accreditation is harder to achieve — which is precisely what makes it more valuable as a competitive signal.

Hospital and Health System Market

Hospital outpatient pharmacies represent the fastest-growing segment of URAC-accredited specialty pharmacies (27% of all accredited facilities in 2024, up from 15% in 2017). URAC's institutional governance standards and clinical quality measurement framework align naturally with health system quality infrastructure. If you are a hospital or IDN building a specialty pharmacy program, URAC is the more established pathway.

Legislative Shield

North Carolina Session Law 2025-69 specifically names URAC accreditation as providing legal protection against PBM credentialing overreach. No equivalent statute exists for ACHC. As FTC and state legislative scrutiny of PBM anti-competitive practices increases, URAC's statutory recognition provides an additional strategic advantage.

Where ACHC Has the Advantage

ACHC holds advantages in independent pharmacy support infrastructure and operational simplicity.

Independent Pharmacy Ecosystem

ACHC has a strategic partnership with R.J. Hedges & Associates, which provides turnkey compliance support with 55+ tailored policy and procedure templates and 90+ customized forms specifically for independent and DMEPOS pharmacies. If your pharmacy is an independent operation looking for the most plug-and-play compliance pathway, the ACHC ecosystem offers more ready-made infrastructure.

DMEPOS and Adjacent Accreditation

If your pharmacy also provides durable medical equipment, prosthetics, orthotics, or supplies, ACHC offers adjacent DMEPOS accreditation that can be coordinated with specialty pharmacy accreditation. URAC does not have a DMEPOS accreditation program.

Operational Focus

ACHC's standards are structured more around operational pharmacy practice, which can mean a somewhat shorter preparation timeline for pharmacies with strong operational fundamentals but less developed clinical documentation infrastructure. However, this operational focus also means ACHC accreditation carries less clinical differentiation signal to payers.

When to Pursue Dual URAC + ACHC Accreditation

Dual accreditation is becoming standard industry practice, not an exception. Here are the specific scenarios where pursuing both makes strategic sense:

• Limited distribution drug access: Manufacturers of rare disease, orphan drugs, and high-cost biologics increasingly require multiple accreditation validations before granting exclusive dispensing contracts. If a drug you want to dispense requires ACHC and you only hold URAC, you are excluded.
• Maximum PBM network flexibility: While all three major PBMs accept both URAC and ACHC, some smaller PBMs or regional networks may prefer one over the other. Dual accreditation eliminates any possibility of accreditation-based network exclusion.
• Competitive differentiation: In a market with roughly 1,900 accredited specialty pharmacy dispensing locations, holding both accreditations signals a higher commitment to quality than competitors holding only one.
• Manufacturer confidence: Drug manufacturers evaluating dispensing partners for limited distribution networks view dual accreditation as a stronger quality signal, particularly for cell and gene therapies with complex distribution requirements.

Sequencing and Cost Optimization

If pursuing dual accreditation, start with URAC. The PM module's clinical depth builds documentation infrastructure that can be adapted for ACHC requirements. Core policies — grievance processes, adverse event reporting, quality committee structures, and competency assessments — overlap substantially and can be reused with formatting adjustments.

IHS advises on documentation reuse, timeline coordination, and cost optimization across both programs. Pursuing both simultaneously is possible but increases internal resource demands. Sequential accreditation (URAC first, ACHC 3-6 months later) typically produces better results for organizations with limited compliance staff.

What About The Joint Commission?

The Joint Commission (TJC) also offers pharmacy accreditation and is accepted by OptumRx alongside URAC and ACHC. However, TJC is less commonly pursued for standalone specialty pharmacy accreditation. TJC is most relevant for hospital-based pharmacies that already hold TJC hospital accreditation and want to add specialty pharmacy as a component of their existing TJC relationship. For standalone specialty pharmacies, URAC and ACHC are the dominant choices.

IHS Recommendation: Which Accreditation Should You Pursue?

IHS is a specialized healthcare accreditation consulting firm with over 25 years of URAC and NCQA expertise, and we advise on both URAC and ACHC pathways. Here is our recommendation framework:

• Commercial payer network access is your primary goal: Start with URAC. 66% of commercial payers prefer it.
• You are a hospital outpatient pharmacy: Start with URAC. The institutional governance alignment and 340B pathway make it the natural fit.
• You need limited distribution drug access: Pursue dual URAC + ACHC. Manufacturers increasingly require both.
• You are a small independent pharmacy: Evaluate URAC's Small Business program first. If ACHC is required by a specific manufacturer or payer, add it.
• You need DMEPOS accreditation alongside specialty pharmacy: Start with ACHC for the DMEPOS-adjacent coordination, then add URAC for commercial payer preference.
• You operate in North Carolina: URAC first — Session Law 2025-69 provides statutory protection against PBM credentialing overreach specifically for URAC-accredited pharmacies.

For a detailed cost comparison, see our URAC Specialty Pharmacy Accreditation Cost Guide. For the full URAC accreditation process breakdown, see our URAC Specialty Pharmacy Accreditation service page.

Ready to Get Started?

Schedule a no-obligation Standard-by-Standard Review with IHS. We will assess your current compliance posture, recommend whether URAC, ACHC, or dual accreditation is the right strategy for your pharmacy, and give you a clear roadmap to accreditation.

Schedule a Free Discovery Session